Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PYPD - PolyPid Ltd.

Previous close
2.7
0   0%

Share volume: 0
Last Updated: Thu 26 Dec 2024 07:48:50 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 1.30%

PREVIOUS CLOSE
CHG
CHG%
$2.70
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
11%
Profitability 0%
Dept financing 16%
Liquidity 50%
Performance 10%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-19.29%
1 Month
-15.26%
3 Months
-17.53%
6 Months
-27.21%
1 Year
-17.73%
2 Year
310.67%
Key data
Stock price
$2.70
P/E Ratio 
0.00
DAY RANGE
$3.39 - $3.52
EPS 
$0.00
52 WEEK RANGE
$2.53 - $9.20
52 WEEK CHANGE
-$22.25
MARKET CAP 
17.030 M
YIELD 
N/A
SHARES OUTSTANDING 
4.797 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$58,265
AVERAGE 30 VOLUME 
$40,638
Company detail
CEO: Dikla C. Akselbrad
Region: US
Website: polypid.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

PolyPid Ltd. develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs)

Recent news